AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors Meeting Abstract
| Authors: | Mitchell, S.; Khan, B.; Payumo, F.; Chiorean, E. G.; Gahvari, Z.; Hecht, J. R.; Hurwitz, M. E.; Leidner, R.; Lenz, H. J.; Pelster, M.; Punekar, S. R.; Schoenfeld, A. J.; Zhao, D.; Vallaster, M. P.; Nagorsen, D. |
| Abstract Title: | AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557406375 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.TPS8650 |
| Notes: | Meeting Abstract: TPS8650 -- Source: Wos |
